NANOBIOTIX honored at the INVESTOR AWARDS 2013 in the “Young Talent” category
News Nov 08, 2013

Nanobiotix was judged as the company, outside of the CAC 40, that achieved the most successful and most promising IPO of the year. The Company came first in this category for successfully meeting the main criteria: corporate profile, leadership in its business activity and financial health.
“It is an honor to receive this award from the Investor Awards panel,” said Laurent Levy, CEO and co-founder of Nanobiotix. “This award reflects the success of the Nanobiotix IPO in October 2012, where many investors showed an interest in our breakthrough technology in nanomedicine for local cancer treatment. We remain focused on the clinical development of our products, which positions us as a leader in nanomedicine. We are also preparing for the challenges around the marketing of our lead product, NBTXR3, which could occur in 2017.”
This prize was awarded by Boursorama and Morningstar that jointly organize the largest survey that selects listed companies by individual and professional investors’ preferences.
The online survey was conducted with investors by OpinionWay in May 2013. In total, more than 40,000 votes were collected (two-thirds of individuals and a third of professionals).
RELATED ARTICLES
The Protein Lasso Implicated in Breast Cancer
NewsCertain types of RNA are implicated in the production of pro-breast cancer proteins. Now, a new study has shed light on the mechanism by which these RNAs manipulate DNA to produce these proteins.
READ MORENew Target for Immunotherapy for Solid Tumors?
NewsResearch from the University of Cincinnati (UC) reveals a potential new target to help T cells (white blood cells) infiltrate certain solid tumors.
READ MOREGene-edited Organoids Reveal How Deadly Brain Cancer Grows
NewsGlioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers. Researchers have now taken an important step towards meeting that challenge.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Applied SciencesTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Login
You must be logged in to post a comment.